Noticias y eventos de Incyte Corp (INCY)

$113.070

-0.204 (-0.18%)Al cierre

Noticias de INCY

8.510-15stocktwits

Verastem Oncology Raises Price Target to $22 Amid Positive Drug Update

5.009-28PRnewswire

MiniMed Appoints New General Counsel

9.009-28stocktwits

FDA Decisions Loom for Bristol Myers and Others

9.009-27NASDAQ.COM

FDA Approves Atebrioz for Rare Disease Treatment

9.009-27NASDAQ.COM

FDA Approves Olumiant for Pediatric Alopecia Areata Treatment

8.509-25Newsfilter

FDA Approves ALK2 Inhibitor Atebrioz for FOP Treatment

9.009-25stocktwits

Analysis of Zilurgisertib Drug Approval Impact

8.509-22Newsfilter

Incyte to Present Data at EADV 2026 Conference

9.009-21stocktwits

Merck Awaits FDA Decision on Winrevair Expansion

7.509-21NASDAQ.COM

Specialised Therapeutics Expands Partnership with Incyte for OPZELURA in Australia

Ver más noticias

Eventos de INCY

9/28 09:30

MiniMed Appoints Sheila Denton as General Counsel

MiniMed (MMED) announced that Sheila Denton has been named General Counsel & Corporate Secretary. Denton brings broad-ranging expertise in corporate governance, strategic transactions, intellectual property, and litigation. Most recently, she served as General Counsel, Corporate Secretary, and a member of the Executive Team of Incyte (INCY).

9/25 19:30

Mirum and Incyte Receive FDA Approval for Atebrioz Drug

Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced that the U.S. FDA has approved Atebrioz tablets to reduce the volume of total new heterotopic ossification in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva. The recommended dose of Atebrioz is 100 mg administered orally, once daily.

9/25 15:00

FDA Approves Atebrioz Tablets for Heterotopic Ossification

The U.S. Food and Drug Administration announced it has approved Atebrioz tablets to reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva, a rare genetic disease caused by a mutation in activin A receptor-type 1, which controls new bone growth. The recommended starting dosage is 100 mg orally once daily with or without food. Atebrioz received fast track, priority review and orphan drug designation for this indication.

9/20 18:30

Specialised Therapeutics Expands Partnership with Incyte

Independent biopharmaceutical company Specialised Therapeutics announced an expansion of its existing partnership with Incyte Biosciences International, an affiliate of Incyte, to commercialize, distribute, and register ruxolitinib cream in Australia. Under the terms of the expanded agreement, Incyte will remain responsible for the development and manufacturing of ruxolitinib cream, while ST will manage regulatory submissions, medical affairs, marketing, and distribution across Australia.

8/19 11:00

RBC Capital Expects Incyte to Update KRAS G12D Data

Incyte (INCY) is expected to report updated data for KRAS G12D inhibitor '734, in combination with mFOLFIRINOX and GemNabP, at ESMO in October, with previous data showing "too little" to have drawn any meaningful conclusions, RBC Capital tells investors in a research note. The firm, which has a Sector Perform rating and $109 price target on Incyte shares, believes the update will look "very competitive" and support the ongoing phase III efforts in 1L PDAC and that initial data appears generally comparable to Revolution Medicines' (RVMD) zoldonrasib.

Ver más eventos

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.